1. Selection must be made prior to the opening bell on the first trading day of the week. 2. Selection may be changed up to the opening bell. 3. Starting price is the opening price on first trading day of week. 4. Ending price is closing price on last trading day of week. 5. No options or other trading vehicles. Only stocks and ETFs are allowed. 6. Opening prices will be those found at Yahoo Finance. Any disputed opening price will be resolved using the price listed at Yahoo Finance historical quotes
To enter the game:
List your stock's symbol, Long or Short, Company name, what the company does and why you like the selection.
Vontier Corporation engages in the research and development, manufacture, sale, and distribution of critical technical equipment, components, software, and services for manufacturing, repair, and servicing in the mobility infrastructure industry worldwide
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. The company is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.